Optimisation of antihypertensive treatment by crossover rotation of four major classes

Lancet

Volumn 353, Issue 9169, 1999, Pages 2008-2013

  Dickerson, J E Claire ^a   Hingorani, Aroon D ^a   Ashby, Michael J ^a   Palmer, Christopher R ^b   Brown, Morris J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; LISINOPRIL; NIFEDIPINE;

ADULT; ADVERSE DRUG REACTION; ARTICLE; CLINICAL TRIAL; CROSSOVER PROCEDURE; DRUG REEXPOSURE; DRUG RESPONSE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL;

EID: 0033549296     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)07614-4     Document Type: Article

References (34)

1. Neaton J.D., Grimm R.H., Prineas R.J.et al. Treatment of mild hypertension study: final results. JAMA. 270:1993;713-724.
2. Bidiville J., Nussberger J., Waeber G., Porchet M., Waeber B., Brunner H.R. Individual responses to converting enzyme inhibitors and calcium antagonists. Hypertension. 11:1988;166-173.
3. Edmonds D., Huss R., Jeck T., Mengden T., Schubert M., Vetter W. Individualizing antihypertensive therapy with enalapril versus atenolol: the Zurich experience. J Hypertens. 8(suppl 4):1990;S49-S52.
4. Niutta E., Cusi D., Colombo R.et al. Predicting interindividual variations in antihypertensive therapy: the role of sodium transport systems and renin. J Hypertens. 8(suppl 4):1990;S53-S58.
5. Waeber B., Burnier M., Nussberger J., Brunner H.R. Trials using a crossover design and ambulatory blood pressure recordings to determine the efficacy of antihypertensive agents in individual patients. J Hypertens. 8(suppl 4):1990;S37-S41.
6. Cappuccio F.P., Markandu N.D., Singer D.R.J., MacGregor G.A. Amlodipine and lisinopril in combination for the treatment of essential hypertension: efficacy and predictors of response. J Hypertens. 11:1993;839-847.
7. Attwood S., Bird R., Burch K.et al. Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens. 12:1994;1053-1060.
8. Laragh J.H., Lamport B., Sealey J., Alderman M.H. Diagnosis ex juvantibus: individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension. 12:1988;223-226.
9. Brunner H.R., Ménard J., Waeber B.et al. Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. J Hypertens. 8:1990;3-11.
10. Chalmers J., Wing L., Taylor S. Analysis of time trends, individual subject responses and background variation in crossover factorial studies with antihypertensive drugs. J Hypertens. 8(suppl 4):1990;S27-S35.
11. de Leeuw P.W., Notter T., Zilles P. Comparison of different fixed antihypertensive combination drugs: a double-blind, placebo-controlled parallel group study. J Hypertens. 1:1997;87-91.
12. Mancia G., Failla M., Grappiolo A., Giannattasio C. Present and future role of combination treatment in hypertension. J Cardiovasc Pharmacol. 31(suppl 2):1998;S41.
13. Jenner D.A., Brown M.J., Lhoste F.J.M. Determination of α-methyldopa, α-methyl-nordrenaline, noradrenaline and adrenaline in plasma using high performance liquid chromatography with electrochemical detection. J Chromatogr. 224:1981;507-512.
14. Giese J., Jörgensen M., Damkjaer Nielsen M., Lund J.O., Munck O. Plasma renin concentration measured by use of radioimmunoassay for angiotensin 1. Scand J Clin Lab Invest. 26:1970;355-367.
15. Brown M.J. The causes of essential hypertension. Br J Clin Pharmacol. 42:1996;21-27.
16. Senn S. Cross-over trials in clinical research. 1993;John Wiley, Chichester.
17. Gill J.S., Zezulka A.V., Beevers D.G., Davis P. Relation between initial blood pressure and its fall with treatment. Lancet. i:1985;567-569.
18. Sever P., Beevers G., Bulpitt C.et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ. 306:1993;983-987.
19. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. 157:1997;2413-2446.
20. 1993 Guidelines for the management of mild hypertension: memorandum from a World Health Organisation/International Society of Hypertension meeting. J Hypertens. 11:1993;905-918.
21. Joffres M.R., Hamet P., Rabkin S.W.et al. Prevalence, control and awareness of high blood pressure among Canadian adults. Can Med Assoc J. 146:1992;1997-2005.
22. Stockwell D.H., Madhaven S., Cohen H., Gibson G., Alderman M.H. The determinants of hypertension awareness, treatment, and control in an insured population. Am J Public Health. 84:1994;1768-1774.
23. Nieto F.J., Alonso J., Chambless L.E.et al. Population awareness and control of hypertension and hypercholesterolemia: the Atherosclerosis Risk in Communities Study. Arch Intern Med. 155:1995;677-684.
24. Guyatt G., Sackett D., Taylor W., Chong J., Roberts R., Pugsley S. Determining optimal therapy - randomized trials in individual patients. N Engl J Med. 314:1986;889-892.
25. Bühler F.R., Burkart F., Lütold B.E., Küng M., Marbet G., Pfisterer M. Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenic mechanisms in essential hypertension. Am J Cardiol. 36:1975;653-669.
26. Laragh J.H., Letcher R.L., Pickering T.G. Renin profiling for diagnosis and treatment of hypertension. JAMA. 241:1979;151-156.
27. Materson B.J., Reda D.J., Cushman W.C. Department of Veterans Affairs single-drug therapy of hypertension study: revised figures and new data. Am J Hypertens. 8:1995;189-192.
28. Beard K., Bulpitt C., Mascie-Taylor H., O'Malley K., Sever P., Webb S. Management of elderly patients with sustained hypertension. BMJ. 304:1992;412-416.
29. Seedat Y.K. Varying responses to hypotensive agents in different racial groups: black versus white differences. J Hypertens. 7:1989;515-518.
30. Brogden R.N., McTavish D. Nifedipine Gastrointestinal Therapeutic System (GITS): a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pectoris. Drugs. 50:1995;495-512.
31. Hingorani A.D., Jia H., Stevens P.A., Hopper R., Dickerson J.E.C., Brown M.J. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertens. 13:1995;1602-1609.
32. Jia H., Hingorani A.D., Sharma P.et al. Association of the Gsα gene with adenylyl cyclase activity, essential hypertension and response to beta blockade. Hypertension. . in press.
33. Gadallah M.F., Abreo K., Work J. Liddle's syndrome, an under-recognised entity: a report of four cases, including the first report in black individuals. Am J Kidney Dis. 25:1995;829-835.
34. Dickerson J.E.C., Brown M.J. Influence of age on general practitioners' definition and treatment of hypertension. BMJ. 310:1995;574.